Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's

Summary
(MedPage Today) -- Diranersen, an investigational antisense oligonucleotide therapy that targets tau, continued to show benefits for 96 weeks, data from the open-label extension of the phase II CELIA trial suggested. At 2 years, diranersen continued...
Description from Medpagetoday.
Who is covering this
-
Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's
(MedPage Today) -- Diranersen, an investigational antisense oligonucleotide therapy that targets tau, continued to show benefits for 96 weeks, data from the open-label extension of the phase II CELIA trial suggested. At 2 years, diranersen continued...
Comments
Comments need JavaScript.